Literature DB >> 28161667

Aerodynamic properties and in silico deposition of meloxicam potassium incorporated in a carrier-free DPI pulmonary system.

Anita Chvatal1, Árpád Farkas2, Imre Balásházy2, Piroska Szabó-Révész1, Rita Ambrus3.   

Abstract

Dry powder inhalers (DPIs) have been among the fastest developing inhaler forms in the past decades. Researches are focusing on the formulation of carrier-free powders to obtain a higher deep-lung deposition and hereby to increase the effectiveness of the medicine. The aim of our study was to prepare a carrier-free dry powder formulation of meloxicam potassium (MP), a novel salt form of meloxicam, using a one-step co-spray drying technology. Different types of excipients were used to modify the crystal structure and to increase aerosolization efficacy. Micrometric properties and the crystal structure were characterized. Aerodynamic properties were tested in vitro using an Andersen Cascade Impactor. A new in silico Stochastic Lung Model was also applied to quantify the amount of particles deposited at the target area. The results have shown that formulated DPI samples are fulfilling the requirements of effective pulmonary drug delivery: they include spherical particles with low density and 1-5μm size distribution. The in silico deposition results correspond with the in vitro measurements and demonstrate that the engineered microcomposites reach a high lung deposition. MP offers a novel opportunity for a well-controlled DPI formulation prepared by a solution-based co-spray drying method.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carrier-free formulation; Co-spray drying; Dry powder inhalation; In silico assessment; Meloxicam potassium

Mesh:

Substances:

Year:  2017        PMID: 28161667     DOI: 10.1016/j.ijpharm.2017.01.070

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  2 in total

1.  Formulation and In Vitro and In Silico Characterization of "Nano-in-Micro" Dry Powder Inhalers Containing Meloxicam.

Authors:  Petra Party; Csilla Bartos; Árpád Farkas; Piroska Szabó-Révész; Rita Ambrus
Journal:  Pharmaceutics       Date:  2021-02-03       Impact factor: 6.321

2.  Development of an Innovative, Carrier-Based Dry Powder Inhalation Formulation Containing Spray-Dried Meloxicam Potassium to Improve the In Vitro and In Silico Aerodynamic Properties.

Authors:  Edit Benke; Árpád Farkas; Piroska Szabó-Révész; Rita Ambrus
Journal:  Pharmaceutics       Date:  2020-06-10       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.